Stress Urinary Incontinence, Vulvovaginal Signs and Symptoms
Conditions
Brief summary
Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Stress Urinary Incontinence and Vulvovaginal Atrophy
Detailed description
The objective of this trial is to evaluate the safety and efficacy of the MorpheusV Applicator for Symptoms of Stress Urinary Incontinence and Vulvovaginal Atrophy
Interventions
DEVICEMorpheusV Applicator
1 treatment with the MorpheusV Applicator
Sponsors
InMode MD Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Eligible subjects will receive 1 treatment with the MorpheusV Applicator according to the study protocol.
Eligibility
Sex/Gender
FEMALE
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent to participate in the study. * Female subjects, 35 and 75 years of age at the time of enrolment with primary and moderate to severe symptoms of SUI, who had scored at least 6 out of 12 according to severity index developed by Sandvik * She has produced a leak during the bladder cough stress test. * 18 out of 27 for the Stress Incontinence Questions and were confirmed as having predominant SUI on the Medical, Epidemiologic, and Social Aspects of Aging Urinary Incontinence (MESA) Questionnaire completed at the screening assessment. * General good health confirmed by medical history and skin examination of the treated area. * The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period.
Exclusion criteria
* \- Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. * Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance, unless deep enough in the periostal plane. * Current or history of cancer, or premalignant condition in the treatment area. * Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases. * Pregnancy and nursing. * Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications. * Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen. * Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction. * Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. * History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. * History of bleeding coagulopathies or use of anticoagulants in the last 10 days. * Any surgery in treated area within 3 months prior to treatment. * Simultaneous participation in another investigator drug or device study or completion of the follow-up phase for the primary endpoint of any previous study less than 30 days prior to the first evaluation in this study. * Six months delay is required if other recent treatments like light, CO2 laser or RF were performed on the same area. * Use of Isotretinoin (Accutane®) within 6 months prior to treatment. * As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of histological changes to vaginal canal tissue | Day 0, month 3 | Evaluation of histological changes to vaginal canal tissue taken immediately post treatment and at 3M FU versus baseline. (for 5 subjects) |
| The effect of the treatment on urinary symptoms by means of Urogenital Distress Inventory 6 Questionnaire | day 0, month 6 | The effect of the treatment on urinary symptoms by means of Urogenital Distress Inventory 6 Questionnaire. Administered at baseline and at 6M FU. |
| The effect of the treatment on urinary symptoms by means of Bladder voiding diary after the treatment | Day 0, month 6 | The effect of the treatment on urinary symptoms by means of Bladder voiding diary after the treatment, and at 6M FU versus baseline. |
| The effect of the treatment on urinary symptoms by means of Medical, Epidemiologic, and Social Aspects of Aging Urinary Incontinence (MESA) Questionnaire | Day 0, month 6 | The effect of the treatment on urinary symptoms by means of Medical, Epidemiologic, and Social Aspects of Aging Urinary Incontinence (MESA) Questionnaire at 6M FU versus baseline. |
| An objective change as measured by standardized cough stress test | Day 0, Month 6 | An objective change as measured by standardized cough stress test performed in standing position before treatment and at 6 months (6M FU) after the treatment |
| An objective evaluation of vaginal atrophy/estrogenization | Day 0, month 6 | An objective evaluation of vaginal atrophy/estrogenization measured by the globally validated Vaginal Health Index (VHI) score at 6M FU compared to Baseline. |
| The effect of the treatment on urinary symptoms and quality of life by means of the Incontinence Quality of Life (IQOL) Questionnaire | Day 0, month 6 | The effect of the treatment on urinary symptoms and quality of life by means of the Incontinence Quality of Life (IQOL) Questionnaire. Administered at baseline and at 6M FU. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Discomfort scale | day 0 | A 10cm visual analog scale from 0 (no discomfort) to 10 (worst possible discomfort) to measure discomfort associated with probe insertion, and RF energy application |
| Adverse Events | Through study completion, an average of 6 months | Number, severity and type of any adverse event recorded throughout the course of the study. |
| Occurrence of expected post treatment immediate response | day 0, through study completion, on average 6 months | Occurrence of expected post treatment immediate response including erythema and edema and during all study period based on predefined scale |
Countries
United States
Outcome results
None listed